{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:02:21Z","timestamp":1790740941566,"version":"4.1.0"},"reference-count":129,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T00:00:00Z","timestamp":1785024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.tranon.2026.102947","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T03:07:02Z","timestamp":1785294422000},"page":"102947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["MET-Aberrant non-small cell lung cancer: from kinase dependence to cell-surface targetability\u2014mechanistic basis and biomarker framework for bispecific antibodies and antibody-drug conjugates"],"prefix":"10.1016","volume":"72","author":[{"given":"Haoyu","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaning","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanming","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102947_bib0001","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark. Res."},{"key":"10.1016\/j.tranon.2026.102947_bib0002","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2147\/OTT.S231257","article-title":"MET oncogene in non-small cell lung cancer: mechanism of MET dysregulation and agents targeting the HGF\/c-met axis","volume":"13","author":"Liang","year":"2020","journal-title":"Onco Targets. Ther."},{"key":"10.1016\/j.tranon.2026.102947_bib0003","doi-asserted-by":"crossref","first-page":"4826","DOI":"10.1002\/cncr.33159","article-title":"The METeoric rise of MET in lung cancer","volume":"126","author":"Friedlaender","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2026.102947_bib0004","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/cancers18020207","article-title":"Targeting mesenchymal-epidermal transition (MET) aberrations in non-small cell lung cancer: current challenges and therapeutic advances","volume":"18","author":"Deng","year":"2026","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.102947_bib0005","article-title":"Overall survival in advanced epidermal growth factor receptor mutated non-small cell lung cancer using different tyrosine kinase inhibitors in The Netherlands: a retrospective, nationwide registry study, The Lancet regional health","volume":"27","author":"Gijtenbeek","year":"2023","journal-title":"Europe"},{"key":"10.1016\/j.tranon.2026.102947_bib0006","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102947_bib0007","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/311029a0","article-title":"Molecular cloning of a new transforming gene from a chemically transformed human cell line","volume":"311","author":"Cooper","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2026.102947_bib0008","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1200\/JCO-24-02413","article-title":"Erratum: clonal MET amplification as a determinant of tyrosine kinase inhibitor resistance in epidermal growth factor receptor-mutant non-small-cell lung cancer","volume":"42","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0009","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41416-023-02475-9","article-title":"Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies","volume":"130","author":"Leonetti","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102947_bib0010","doi-asserted-by":"crossref","first-page":"772","DOI":"10.3390\/genes16070772","article-title":"Management of MET-driven resistance to Osimertinib in EGFR-mutant non-small cell lung cancer","volume":"16","author":"Angelopoulos","year":"2025","journal-title":"Genes"},{"key":"10.1016\/j.tranon.2026.102947_bib0011","doi-asserted-by":"crossref","first-page":"612","DOI":"10.3390\/cancers15030612","article-title":"MET amplification as a resistance driver to TKI therapies in lung cancer: clinical challenges and opportunities","volume":"15","author":"Qin","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.tranon.2026.102947_bib0012","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyae357","article-title":"Emerging molecular testing paradigms in non-small cell lung cancer management-current perspectives and recommendations","volume":"30","author":"Penault-Llorca","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2026.102947_bib0013","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41698-025-01144-9","article-title":"MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer","volume":"9","author":"Tsao","year":"2025","journal-title":"NPJ. Precis. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0014","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1023\/A:1023768811842","article-title":"c-met: structure, functions and potential for therapeutic inhibition","volume":"22","author":"Ma","year":"2003","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.tranon.2026.102947_bib0015","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1126\/science.1141478","article-title":"MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling","volume":"316","author":"Engelman","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.tranon.2026.102947_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100641","article-title":"Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET","volume":"296","author":"Neijssen","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tranon.2026.102947_bib0017","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s11912-022-01266-4","article-title":"Bystander effect of antibody-drug conjugates: fact or fiction?","volume":"24","author":"Giugliano","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.tranon.2026.102947_bib0018","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab Vedotin monotherapy in patients with previously treated c-met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0019","doi-asserted-by":"crossref","DOI":"10.3390\/ph17040448","article-title":"The MET oncogene: thirty years of insights into molecular mechanisms driving malignancy","volume":"17","author":"Crepaldi","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tranon.2026.102947_bib0020","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.21037\/tlcr-23-288","article-title":"Telisotuzumab vedotin with erlotinib in the treatment of non-small cell lung cancer: a well MET combination?","volume":"12","author":"Kujtan","year":"2023","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.tranon.2026.102947_bib0021","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1016\/j.apsb.2023.05.023","article-title":"Bispecific antibodies in cancer therapy: target selection and regulatory requirements","volume":"13","author":"Sun","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.tranon.2026.102947_bib0022","doi-asserted-by":"crossref","first-page":"9674","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2026.102947_bib0023","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.671","article-title":"Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies","volume":"5","author":"He","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.tranon.2026.102947_bib0024","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41698-025-01159-2","article-title":"Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology","volume":"9","author":"Lu","year":"2025","journal-title":"NPJ. Precis. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0025","doi-asserted-by":"crossref","first-page":"841","DOI":"10.3390\/cancers15030841","article-title":"Osimertinib resistance: molecular mechanisms and emerging treatment options","volume":"15","author":"Gomatou","year":"2023","journal-title":"Cancers."},{"key":"10.1016\/j.tranon.2026.102947_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100319","article-title":"Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer","volume":"6","author":"Coleman","year":"2021","journal-title":"ESMo Open."},{"key":"10.1016\/j.tranon.2026.102947_bib0027","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jtho.2016.06.004","article-title":"Characterization of 298 patients with lung cancer harboring MET exon 14 skipping alterations","volume":"11","author":"Schrock","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0028","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.lungcan.2018.07.006","article-title":"Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer - A systematic review and meta-analysis","volume":"123","author":"Vuong","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2026.102947_bib0029","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cllc.2023.06.008","article-title":"MET Exon 14 skipping in NSCLC: a systematic literature Review of epidemiology, clinical characteristics, and outcomes","volume":"24","author":"Mazieres","year":"2023","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.tranon.2026.102947_bib0030","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.21037\/tlcr-20-1113","article-title":"A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations","volume":"10","author":"Santarpia","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.tranon.2026.102947_bib0031","doi-asserted-by":"crossref","first-page":"16098","DOI":"10.1016\/S0021-9258(18)98521-2","article-title":"Intracellular calcium regulates the tyrosine kinase receptor encoded by the MET oncogene","volume":"266","author":"Gandino","year":"1991","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tranon.2026.102947_bib0032","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1042\/BST20253091","article-title":"Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression","volume":"53","author":"Ghosh","year":"2025","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.tranon.2026.102947_bib0033","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1158\/2159-8290.CD-15-0285","article-title":"Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors","volume":"5","author":"Frampton","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tranon.2026.102947_bib0034","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-019-0716-8","article-title":"Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration","volume":"26","author":"Drilon","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2026.102947_bib0035","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa2002787","article-title":"Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer","volume":"383","author":"Wolf","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102947_bib0036","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1056\/NEJMoa2004407","article-title":"Tepotinib in non-small-cell lung cancer with MET exon 14 skipping mutations","volume":"383","author":"Paik","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102947_bib0037","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jtho.2016.09.119","article-title":"Emergence of preexisting MET Y1230C mutation as a resistance mechanism to Crizotinib in NSCLC with MET exon 14 skipping","volume":"12","author":"Ou","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0038","doi-asserted-by":"crossref","first-page":"5255","DOI":"10.1158\/0008-5472.CAN-10-4433","article-title":"A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients","volume":"71","author":"Tiedt","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102947_bib0039","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1158\/1078-0432.CCR-19-3608","article-title":"Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14-mutant NSCLC","volume":"26","author":"Recondo","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102947_bib0040","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1158\/1078-0432.CCR-15-2061","article-title":"MET amplification and exon 14 splice site mutation define unique molecular subgroups of non-small cell lung carcinoma with poor prognosis","volume":"22","author":"Tong","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102947_bib0041","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41571-020-0377-z","article-title":"MET-dependent solid tumours - molecular diagnosis and targeted therapy","volume":"17","author":"Guo","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0042","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.jtho.2025.05.012","article-title":"Amivantamab in participants with advanced NSCLC and MET exon 14 skipping mutations: final results from the CHRYSALIS study","volume":"20","author":"Krebs","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0043","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jtho.2019.06.009","article-title":"MET IHC is a poor screen for MET amplification or MET exon 14 mutations in lung adenocarcinomas: data from a tri-institutional cohort of the Lung Cancer mutation Consortium","volume":"14","author":"Guo","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0044","doi-asserted-by":"crossref","first-page":"i10","DOI":"10.1093\/annonc\/mdx703","article-title":"Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors","volume":"29","author":"Westover","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0045","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.cllc.2014.12.013","article-title":"Current and future approaches in the management of non-small-cell lung cancer patients with resistance to EGFR TKIs","volume":"16","author":"Matikas","year":"2015","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.tranon.2026.102947_bib0046","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.lungcan.2019.09.019","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: a multicentric retrospective French study","volume":"137","author":"Mehlman","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2026.102947_bib0047","doi-asserted-by":"crossref","first-page":"6336","DOI":"10.1158\/1078-0432.CCR-14-1293","article-title":"Analysis of 1115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic","volume":"20","author":"Jardim","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102947_bib0048","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.jtho.2016.04.033","article-title":"Identifying the appropriate FISH criteria for defining MET copy number-driven lung adenocarcinoma through oncogene overlap analysis","volume":"11","author":"Noonan","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100451","article-title":"Unraveling the significance of MET focal amplification in lung cancer: integrative NGS, FISH, and IHC investigation","volume":"37","author":"Xiang","year":"2024","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.tranon.2026.102947_bib0050","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/annonc\/mdz407","article-title":"Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcS\u00e9 phase II trial","volume":"30","author":"Moro-Sibilot","year":"2019","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0051","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/jcp.25794","article-title":"C-met as a potential target for the treatment of gastrointestinal cancer: current status and future perspectives","volume":"232","author":"Bahrami","year":"2017","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.tranon.2026.102947_bib0052","article-title":"Beta 1-integrin-c-met cooperation reveals an inside-in survival signalling on autophagy-related endomembranes","volume":"7","author":"Barrow-McGee","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2026.102947_bib0053","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41571-025-01051-9","article-title":"Evolving roles of MET as a therapeutic target in NSCLC and beyond","volume":"22","author":"Lee","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0054","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0169-5002(98)00007-5","article-title":"Differential expression of met\/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers","volume":"20","author":"Tsao","year":"1998","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2026.102947_bib0055","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1038\/s41388-018-0185-4","article-title":"The multiple paths towards MET receptor addiction in cancer","volume":"37","author":"Duplaquet","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2026.102947_bib0056","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/j.1349-7006.2007.00493.x","article-title":"c-met activation in lung adenocarcinoma tissues: an immunohistochemical analysis","volume":"98","author":"Nakamura","year":"2007","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tranon.2026.102947_bib0057","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/S2213-2600(20)30154-5","article-title":"Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b\/2, multicentre, randomised trial","volume":"8","author":"Wu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.tranon.2026.102947_bib0058","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1158\/2159-8290.CD-22-0586","article-title":"Osimertinib + Savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON","volume":"13","author":"Hartmaier","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tranon.2026.102947_bib0059","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jtho.2024.12.029","article-title":"Amivantamab plus Lazertinib in patients with EGFR-mutant NSCLC after progression on Osimertinib and platinum-based chemotherapy: results from CHRYSALIS-2 cohort A","volume":"20","author":"Besse","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0060","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.annonc.2023.10.117","article-title":"Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0061","doi-asserted-by":"crossref","first-page":"5053","DOI":"10.1158\/0008-5472.CAN-12-3775","article-title":"EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis","volume":"73","author":"Breindel","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102947_bib0062","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/0008-5472.CAN-05-2749","article-title":"Somatic mutations lead to an oncogenic deletion of met in lung cancer","volume":"66","author":"Kong-Beltran","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102947_bib0063","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231216096","article-title":"Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer","volume":"16","author":"Bai","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0064","article-title":"The landscape of MET exon 14 skipping mutations in patients with lung cancer identified by next-generation sequencing","volume":"6","author":"Liao","year":"2025","journal-title":"JTo Clin. Res. Rep."},{"key":"10.1016\/j.tranon.2026.102947_bib0065","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.jtho.2017.07.026","article-title":"MET Exon 14 alterations and new resistance mutations to tyrosine kinase inhibitors: risk of inadequate detection with current amplicon-based NGS panels","volume":"12","author":"Poirot","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0066","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jtho.2018.12.020","article-title":"DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer","volume":"14","author":"Davies","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0067","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.cllc.2018.10.004","article-title":"Molecular diagnostic assays and clinicopathologic implications of MET exon 14 skipping mutation in non-small-cell lung cancer","volume":"20","author":"Kim","year":"2019","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.tranon.2026.102947_bib0068","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.lungcan.2019.11.010","article-title":"Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer","volume":"140","author":"Pruis","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2026.102947_bib0069","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/j.jtho.2018.05.041","article-title":"Comparison of molecular testing modalities for detection of ROS1 rearrangements in a cohort of positive patient samples","volume":"13","author":"Davies","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0070","doi-asserted-by":"crossref","DOI":"10.2174\/0113894501409916251103161912","article-title":"MET Exon 14 skipping mutation in NSCLC: from genomic discovery to biomarker-guided therapeutic innovation","volume":"27","author":"Huang","year":"2026","journal-title":"Curr. Drug Targets."},{"key":"10.1016\/j.tranon.2026.102947_bib0071","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2144\/btn-2020-0057","article-title":"PCR past, present and future","volume":"69","author":"Zhu","year":"2020","journal-title":"BioTechniques"},{"key":"10.1016\/j.tranon.2026.102947_bib0072","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1677\/jme.0.0250169","article-title":"Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays","volume":"25","author":"Bustin","year":"2000","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.tranon.2026.102947_bib0073","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-61779-126-0_9","article-title":"Quantification of GPCR mRNA using real-time RT-PCR","volume":"746","author":"Brattelid","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tranon.2026.102947_bib0074","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jtho.2022.10.015","article-title":"MET alterations in NSCLC-current perspectives and future challenges","volume":"18","author":"Remon","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0075","first-page":"83","article-title":"Prognostic and predictive value of MET deregulation in non-small cell lung cancer","volume":"3","author":"Finocchiaro","year":"2015","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.tranon.2026.102947_bib0076","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1200\/JCO.2008.19.1635","article-title":"Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients","volume":"27","author":"Cappuzzo","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0077","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/JTO.0b013e3181ce3d1d","article-title":"High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer","volume":"5","author":"Go","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0078","doi-asserted-by":"crossref","first-page":"237","DOI":"10.20892\/j.issn.2095-3941.2024.0503","article-title":"Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration","volume":"22","author":"Feng","year":"2025","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.tranon.2026.102947_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2025.149647","article-title":"Technical innovations of signal amplification in fluorescence in situ hybridization","volume":"964","author":"Ling","year":"2025","journal-title":"Gene"},{"key":"10.1016\/j.tranon.2026.102947_bib0080","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.18632\/oncotarget.28092","article-title":"Comparison of MET gene amplification analysis by next-generation sequencing and fluorescence in situ hybridization","volume":"12","author":"Schmitt","year":"2021","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2026.102947_bib0081","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.tranon.2026.102947_bib0082","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1200\/JCO.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of Patritumab Deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0083","doi-asserted-by":"crossref","first-page":"275","DOI":"10.5582\/ddt.2025.01058","article-title":"Telisotuzumab vedotin: the first-in-class c-met-targeted antibody-drug conjugate granted FDA accelerated approval for treatment of non-squamous non-small cell lung cancer (NSCLC)","volume":"19","author":"Zhao","year":"2025","journal-title":"Drug Discov. Ther."},{"key":"10.1016\/j.tranon.2026.102947_bib0084","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107897","article-title":"NGS and FISH for MET amplification detection in EGFR TKI resistant non-small cell lung cancer (NSCLC) patients: a prospective, multicenter study in China","volume":"194","author":"Zheng","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2026.102947_bib0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/978-1-4939-8935-5_25","article-title":"An introduction to the performance of immunohistochemistry","volume":"1897","author":"Magaki","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tranon.2026.102947_bib0086","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-4939-1050-2_8","article-title":"A practical approach to clinical and research biobanking","volume":"1180","author":"Yong","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.tranon.2026.102947_bib0087","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.5858\/arpa.2014-0074-RA","article-title":"Standardization of diagnostic immunohistochemistry: literature review and geisinger experience","volume":"138","author":"Lin","year":"2014","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.tranon.2026.102947_bib0088","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.lungcan.2013.07.016","article-title":"Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study","volume":"82","author":"Mazi\u00e8res","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tranon.2026.102947_bib0089","doi-asserted-by":"crossref","first-page":"4105","DOI":"10.1200\/JCO.2012.47.4189","article-title":"Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer","volume":"31","author":"Spigel","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0090","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S1470-2045(19)30785-5","article-title":"Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study","volume":"21","author":"Sequist","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0091","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cllc.2025.10.018","article-title":"Savolitinib plus Osimertinib in epidermal growth factor receptor-mutated, MET-amplified advanced non-small cell lung cancer: a randomized Phase II trial","volume":"27","author":"Yang","year":"2026","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.tranon.2026.102947_bib0092","series-title":"FDA Grants Accelerated Approval to Telisotuzumab Vedotin-Tllv For NSCLC With High C-Met Protein Overexpression","year":"2025"},{"key":"10.1016\/j.tranon.2026.102947_bib0093","article-title":"Targeting MET in NSCLC: an ever-expanding territory","volume":"5","author":"Han","year":"2024","journal-title":"JTo Clin. Res. Rep."},{"key":"10.1016\/j.tranon.2026.102947_bib0094","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41568-018-0002-y","article-title":"Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy","volume":"18","author":"Comoglio","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tranon.2026.102947_bib0095","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jtho.2017.12.001","volume":"13","author":"Lindeman","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0096","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","article-title":"ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group","volume":"33","author":"Pascual","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0097","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S1470-2045(24)00441-8","article-title":"Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trial","volume":"25","author":"Wolf","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0098","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jamaoncol.2023.1962","article-title":"Tepotinib treatment in patients with MET exon 14-skipping non-small cell lung cancer: long-term follow-up of the VISION phase 2 nonrandomized clinical trial","volume":"9","author":"Mazieres","year":"2023","journal-title":"JAMa Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0099","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(24)00270-5","article-title":"Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial","volume":"25","author":"Wu","year":"2024","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0100","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(25)01811-2","article-title":"Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial","volume":"407","author":"Lu","year":"2026","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2026.102947_bib0101","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.annonc.2025.04.003","article-title":"Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and\/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study","volume":"36","author":"de Marinis","year":"2025","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0102","doi-asserted-by":"crossref","DOI":"10.3390\/antib13040088","article-title":"Anti-MET antibody therapies in non-small-cell lung cancer: current progress and future directions","volume":"13","author":"Wang","year":"2024","journal-title":"Antibodies"},{"key":"10.1016\/j.tranon.2026.102947_bib0103","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1004198","article-title":"Meeting an un-MET need: targeting MET in non-small cell lung cancer","volume":"12","author":"Michaels","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0104","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s11864-022-01022-7","article-title":"New strategies and novel combinations in EGFR TKI-resistant non-small cell lung cancer","volume":"23","author":"Girard","year":"2022","journal-title":"Curr. Treat. Options. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/10781552251358871","article-title":"Comprehensive management strategies for amivantamab-induced toxicities and review of the literature","volume":"32","author":"Ceylan","year":"2026","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.tranon.2026.102947_bib0106","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41571-024-00971-2","article-title":"The changing treatment landscape of EGFR-mutant non-small-cell lung cancer","volume":"22","author":"Zhou","year":"2025","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0107","doi-asserted-by":"crossref","DOI":"10.3390\/curroncol32070403","article-title":"MET exon 14 skipping mutations in lung cancer: clinical-pathological characteristics and immune microenvironment","volume":"32","author":"Xue","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0108","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1038\/s41591-023-02554-7","article-title":"Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial","volume":"29","author":"Cho","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2026.102947_bib0109","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1200\/JCO.2025.43.16_suppl.8639","article-title":"Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after disease progression on osimertinib: outcomes by osimertinib resistance mechanisms in MARIPOSA-2","volume":"43","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0110","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jtho.2025.09.154","article-title":"MA07.07 Validation analysis of MET IHC as a biomarker for Amivantamab-lazertinib response in post-osimertinib EGFR-mutated NSCLC","volume":"20","year":"2025","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0111","doi-asserted-by":"crossref","first-page":"9027","DOI":"10.21037\/tcr-2025-1007","article-title":"Targeting MET in advanced and metastatic non-small cell lung cancer: a literature review of the current landscape","volume":"14","author":"Herrmann","year":"2025","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102947_bib0112","series-title":"Patients With Advanced NSCLC and Other Solid Tumors","article-title":"Study of MCLA-129, a Human bispecific EGFR and cMet antibody","year":"2024"},{"key":"10.1016\/j.tranon.2026.102947_bib0113","series-title":"EMB-01 in Combination With Osimertinib in Patients With EGFR-mutant NSCLC","year":"2022"},{"key":"10.1016\/j.tranon.2026.102947_bib0114","series-title":"A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer","year":"2020"},{"key":"10.1016\/j.tranon.2026.102947_bib0115","article-title":"Telisotuzumab Vedotin monotherapy in patients with previously treated c-met protein overexpressing, nonsquamous, EGFR wild-type advanced NSCLC: updated analysis of the LUMINOSITY trial","volume":"7","author":"Girard","year":"2026","journal-title":"JTo Clin. Res. Rep."},{"key":"10.1016\/j.tranon.2026.102947_bib0116","article-title":"Telisotuzumab Vedotin monotherapy in patients with previously treated c-met protein overexpressing, nonsquamous, EGFR wild-type advanced NSCLC: updated analysis of the LUMINOSITY trial","volume":"7","author":"Girard","year":"2026","journal-title":"JTo Clin. Res. Rep."},{"key":"10.1016\/j.tranon.2026.102947_bib0117","series-title":"EMRELIS (telisotuzumab vedotin-tllv) Prescribing Information","year":"2025"},{"key":"10.1016\/j.tranon.2026.102947_bib0118","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-18-1640","article-title":"Activation of KRAS mediates resistance to targeted therapy in MET exon 14-mutant non-small cell lung cancer","volume":"25","author":"Suzawa","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102947_bib0119","article-title":"MET alterations detection platforms and clinical implications in solid tumors: a comprehensive review of literature","volume":"16","author":"Yuan","year":"2024","journal-title":"Therap. Adv. Med. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0120","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jtho.2025.01.018","article-title":"Preventing infusion-related reactions with intravenous Amivantamab-results from SKIPPirr, a phase 2 study: a brief report","volume":"20","author":"Spira","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0121","first-page":"1","article-title":"Cutaneous toxicities with Amivantamab for non-small cell lung cancer: a practical guide and best practices","volume":"28","author":"Singh-Kandah","year":"2024","journal-title":"Clin. J. Oncol. Nurs."},{"key":"10.1016\/j.tranon.2026.102947_bib0122","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.24.01001","article-title":"Subcutaneous versus intravenous Amivantamab, both in combination with Lazertinib, in refractory epidermal growth factor receptor-mutated non-small cell lung cancer: primary results from the phase III PALOMA-3 Study","volume":"42","author":"Leighl","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0123","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1097\/PAS.0000000000002274","article-title":"Reproducibility of c-met immunohistochemical scoring (Clone SP44) for non-small cell lung cancer using conventional light microscopy and whole slide imaging","volume":"48","author":"Bontoux","year":"2024","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.tranon.2026.102947_bib0124","article-title":"Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testing procedures, burden, and treatments","volume":"13","author":"Yang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2026.102947_bib0125","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4049\/jimmunol.2200389","article-title":"A novel TrxR1 inhibitor regulates NK and CD8+ T cell infiltration and cytotoxicity, enhancing the efficacy of Anti-PD-1 immunotherapy against hepatocarcinoma","volume":"210","author":"Su","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2026.102947_bib0126","series-title":"A Phase 1 Study Investigating the safety, tolerability, pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR\u00d7MET Trispecific antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors","year":"2024"},{"key":"10.1016\/j.tranon.2026.102947_bib0127","series-title":"NCT04868877: Phase 1\/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination","year":"2021"},{"key":"10.1016\/j.tranon.2026.102947_bib0128","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/cas.70280","article-title":"EMB-01, a tetravalent bispecific antibody, inducing Co-degradation of EGFR and c-met for enhanced anti-tumor efficacy","volume":"117","author":"Gao","year":"2026","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tranon.2026.102947_bib0129","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.21037\/tlcr-24-144","article-title":"REGN5093-M114: can an antibody-drug conjugate overcome the challenge of resistance to epidermal growth factor receptor and mesenchymal epithelial transition tyrosine kinase inhibitors in non-small cell lung cancer?","volume":"13","author":"Dardare","year":"2024","journal-title":"Transl. Lung Cancer Res."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:41:23Z","timestamp":1790739683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326002834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":129,"alternative-id":["S1936523326002834"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102947","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MET-Aberrant non-small cell lung cancer: from kinase dependence to cell-surface targetability\u2014mechanistic basis and biomarker framework for bispecific antibodies and antibody-drug conjugates","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102947"}}